<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="fd318e79-614e-4c0e-a683-b465ab5b8386"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>Ganirelix Acetate Injection<br/>(For Subcutaneous Use Only)
</title>
   <effectiveTime value="20250220"/>
   <setId root="1f067dfb-f9c7-4020-ab7b-da2ba695ab32"/>
   <versionNumber value="7"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="080548348" root="1.3.6.1.4.1.519.1"/>
            <name>Meitheal Pharmaceuticals Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="421297554" root="1.3.6.1.4.1.519.1"/>
                        <name>Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71288-554" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="dcl-dpl">
               <id root="c42dd758-ac3d-4899-90a6-907b91e64131"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20220606"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="71288-554" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Ganirelix Acetate</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Ganirelix Acetate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="250" unit="ug"/>
                              <denominator value="0.5" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="56U7906FQW" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ganirelix acetate</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="IX503L9WN0" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ganirelix</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="23.5" unit="mg"/>
                              <denominator value="0.5" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>mannitol</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="0.1" unit="mg"/>
                              <denominator value="0.5" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="Q40Q9N063P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>acetic acid</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>sodium hydroxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>water</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="0.5" unit="mL"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43203" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE, GLASS"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                                    <asContent>
                                       <quantity>
                                          <numerator value="1" unit="1"/>
                                          <denominator value="1" unit="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code code="71288-554-80" codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                       </containerPackagedProduct>
                                       <subjectOf>
                                          <marketingAct>
                                             <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                             <statusCode code="active"/>
                                             <effectiveTime>
                                                <low value="20220606"/>
                                             </effectiveTime>
                                          </marketingAct>
                                       </subjectOf>
                                    </asContent>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA214996" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <effectiveTime>
                              <low value="20220606"/>
                           </effectiveTime>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20220606"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="s1">
               <id root="473d42b2-614b-48ab-8976-4e8b0c69c9da"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>meitheal<sub>®</sub>
                     <br/>Rx only</paragraph>
               </text>
               <effectiveTime value="20250220"/>
            </section>
         </component>
         <component>
            <section ID="s2">
               <id root="c41f7590-900f-4003-81e2-fd8bf5edf1b7"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION
</title>
               <text>
                  <paragraph>Ganirelix Acetate Injection is a synthetic decapeptide with high antagonistic activity against naturally occurring gonadotropin-releasing hormone (GnRH). Ganirelix acetate is derived from native GnRH with substitutions of amino acids at positions 1, 2, 3, 6, 8, and 10 to form the following molecular formula of the peptide: N-acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-L-tyrosyl-N<sup>9</sup>,N<sup>10</sup>-diethyl-D-homoarginyl-L-leucyl-N<sup>9</sup>, N<sup>10</sup>-diethyl-L-homoarginyl-L-prolyl-D-alanylamide acetate. The molecular weight for ganirelix acetate is 1570.4 as an anhydrous free base. The structural formula is as follows:</paragraph>
                  <paragraph>Ganirelix Acetate</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L71eb3f22-e2eb-43ec-8f69-fcf4c68c96c6"/>
                  </paragraph>
                  <paragraph>
                     <content>Ganirelix Acetate Injection is supplied as a colorless, sterile, ready-to-use, aqueous solution intended for SUBCUTANEOUS administration only. Each single dose, sterile, prefilled syringe contains 250 mcg per 0.5 mL of ganirelix acetate; 0.1 mg glacial acetic acid, USP; 23.5 mg mannitol, USP; and water for injection, USP adjusted to pH 5.0 with glacial acetic acid, USP and/or sodium hydroxide, NF.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250220"/>
               <component>
                  <observationMedia ID="L71eb3f22-e2eb-43ec-8f69-fcf4c68c96c6">
                     <text>Structural Formula</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="gan05-0000-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s3">
               <id root="5fcfb963-21e8-4083-96e0-026e2fba23d0"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY
</title>
               <text>
                  <paragraph>The pulsatile release of GnRH stimulates the synthesis and secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The frequency of LH pulses in the mid and late follicular phase is approximately 1 pulse per hour. These pulses can be detected as transient rises in serum LH. At midcycle, a large increase in GnRH release results in an LH surge. The midcycle LH surge initiates several physiologic actions including: ovulation, resumption of meiosis in the oocyte, and luteinization. Luteinization results in a rise in serum progesterone with an accompanying decrease in estradiol levels.
</paragraph>
                  <paragraph>Ganirelix acetate acts by competitively blocking the GnRH receptors on the pituitary gonadotroph and subsequent transduction pathway. It induces a rapid, reversible suppression of gonadotropin secretion. The suppression of pituitary LH secretion by ganirelix acetate is more pronounced than that of FSH. An initial release of endogenous gonadotropins has not been detected with ganirelix acetate, which is consistent with an antagonist effect. Upon discontinuation of ganirelix acetate, pituitary LH and FSH levels are fully recovered within 48 hours.
</paragraph>
               </text>
               <effectiveTime value="20250220"/>
               <component>
                  <section ID="s4">
                     <id root="128cfd55-a338-481a-91a3-363bb879022e"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>Pharmacokinetics
</title>
                     <text>
                        <paragraph>The pharmacokinetic parameters of single and multiple injections of ganirelix acetate in healthy adult females are summarized in <linkHtml href="#t300">Table I</linkHtml>. Steady-state serum concentrations are reached after 3 days of treatment. The pharmacokinetics of ganirelix acetate are dose-proportional in the dose range of 125 to 500 mcg.</paragraph>
                        <table ID="t300" width="100%">
                           <caption>TABLE I: Mean (SD) pharmacokinetic parameters of 250 mcg of ganirelix acetate following a single subcutaneous (SC) injection (n=15) and daily SC injections (n=15) for seven days.</caption>
                           <colgroup>
                              <col width="21.886%" align="left"/>
                              <col width="11.414%" align="left"/>
                              <col width="13.300%" align="left"/>
                              <col width="12.357%" align="left"/>
                              <col width="13.300%" align="left"/>
                              <col width="13.300%" align="left"/>
                              <col width="14.443%" align="left"/>
                           </colgroup>
                           <tfoot>
                              <tr>
                                 <td colspan="7" align="left" valign="top">
                                    <paragraph styleCode="First Footnote">t<sub>max</sub> Time to maximum concentration</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="7" align="left" valign="top">
                                    <paragraph styleCode="First Footnote">t<sub>½</sub> Elimination half-life</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="7" align="left" valign="top">
                                    <paragraph styleCode="First Footnote">C<sub>max</sub> Maximum serum concentration</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="7" align="left" valign="top">
                                    <paragraph styleCode="First Footnote">AUC Area under the curve; Single dose: AUC<sub>0–∞</sub>; multiple dose: AUC<sub>0–24</sub>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="7" align="left" valign="top">
                                    <paragraph styleCode="First Footnote">V<sub>d</sub> Volume of distribution</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="7" align="left" valign="top">
                                    <paragraph styleCode="First Footnote">
                                       <sup>†</sup> Based on intravenous administration</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="7" align="left" valign="top">
                                    <paragraph styleCode="First Footnote">CL Clearance = Dose/AUC<sub>0–∞</sub>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="7" align="left" valign="top">
                                    <paragraph styleCode="First Footnote">F Absolute bioavailability</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="left" valign="top"/>
                                 <td align="center" valign="top">
                                    <content styleCode="bold">t<sub>max</sub>
                                    </content>
                                    <br/>
                                    <content styleCode="bold">h</content>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">t<sub>1/2</sub>
                                       </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">h</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <content styleCode="bold">C<sub>max</sub>
                                    </content>
                                    <br/>
                                    <content styleCode="bold">ng/mL</content>
                                 </td>
                                 <td align="center" valign="top">
                                    <content styleCode="bold">AUC</content>
                                    <br/>
                                    <content styleCode="bold">ng•h/mL</content>
                                 </td>
                                 <td align="center" valign="top">
                                    <content styleCode="bold">CL/F</content>
                                    <br/>
                                    <content styleCode="bold">L/h</content>
                                 </td>
                                 <td align="center" valign="top">
                                    <content styleCode="bold">V<sub>d</sub>/F</content>
                                    <br/>
                                    <content styleCode="bold">L</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Ganirelix Acetate single dose</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">1.1 (0.3)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">12.8 (4.3)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">14.8 (3.2)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">96 (12)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">2.4 (0.2)<sup>†</sup>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">43.7 (11.4)<sup>†</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Ganirelix Acetate multiple dose</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">1.1 (0.2)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">16.2 (1.6)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">11.2 (2.4)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">77.1 (9.8)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">3.3 (0.4)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">76.5 (10.3)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20250220"/>
                     <component>
                        <section ID="s5">
                           <id root="e3cb721f-1b83-44fb-af1c-6ea91d48edcb"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Absorption</content>
                           </title>
                           <text>
                              <paragraph>Ganirelix acetate is rapidly absorbed following subcutaneous injection with maximum serum concentrations reached approximately one hour after dosing. The mean absolute bioavailability of ganirelix acetate following a single 250-mcg subcutaneous injection to healthy female volunteers is 91.1%.</paragraph>
                           </text>
                           <effectiveTime value="20250220"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s6">
                           <id root="d85082ea-326a-40ef-bc2d-a61071bc2614"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Distribution</content>
                           </title>
                           <text>
                              <paragraph>The mean (SD) volume of distribution of ganirelix acetate in healthy females following intravenous administration of a single 250 mcg dose is 43.7 (11.4) liters (L). <content styleCode="italics">In vitro</content> protein binding to human plasma is 81.9%.</paragraph>
                           </text>
                           <effectiveTime value="20250220"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s7">
                           <id root="02beaa7b-7ad9-47c9-a83b-da77fdcdbc37"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Metabolism</content>
                           </title>
                           <text>
                              <paragraph>Following single-dose intravenous administration of radiolabeled ganirelix acetate to healthy female volunteers, ganirelix acetate is the major compound present in the plasma (50–70% of total radioactivity in the plasma) up to 4 hours and urine (17.1–18.4% of administered dose) up to 24 hours. Ganirelix acetate is not found in the feces. The 1–4 peptide and 1–6 peptide of ganirelix acetate are the primary metabolites observed in the feces.</paragraph>
                           </text>
                           <effectiveTime value="20250220"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s8">
                           <id root="2876fb2c-62ee-4210-aaba-1f46f317c114"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Excretion</content>
                           </title>
                           <text>
                              <paragraph>On average, 97.2% of the total radiolabeled ganirelix acetate dose is recovered in the feces and urine (75.1% and 22.1%, respectively) over 288 h following intravenous single dose administration of 1 mg [<sup>14</sup>C]-ganirelix acetate. Urinary excretion is virtually complete in 24 h, whereas fecal excretion starts to plateau 192 h after dosing.</paragraph>
                           </text>
                           <effectiveTime value="20250220"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s9">
                     <id root="8937542e-849d-4a24-b781-e0c7844f76a0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Special Populations
</title>
                     <text>
                        <paragraph>The pharmacokinetics of ganirelix acetate have not been determined in special populations such as geriatric, pediatric, renally impaired and hepatically impaired patients (see <content styleCode="bold">
                              <linkHtml href="#s16">PRECAUTIONS</linkHtml>
                           </content>).
</paragraph>
                     </text>
                     <effectiveTime value="20250220"/>
                     <component>
                        <section ID="s10">
                           <id root="c1a7cc4e-6aa9-4e61-89d3-ec4ac714af7d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Drug-Drug Interactions</content>
                           </title>
                           <text>
                              <paragraph>Formal <content styleCode="italics">in vivo</content> or <content styleCode="italics">in vitro</content> drug-drug interaction studies have not been conducted (see <content styleCode="bold">
                                    <linkHtml href="#s16">PRECAUTIONS</linkHtml>
                                 </content>). Since ganirelix acetate can suppress the secretion of pituitary gonadotropins, dose adjustments of exogenous gonadotropins may be necessary when used during controlled ovarian hyperstimulation (COH).</paragraph>
                           </text>
                           <effectiveTime value="20250220"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s11">
                     <id root="13e15834-6aa0-4055-81e6-25622310d3e3"/>
                     <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
                     <title>Clinical Studies
</title>
                     <text>
                        <paragraph>The efficacy of ganirelix acetate was established in two adequate and well-controlled clinical studies which included women with normal endocrine and pelvic ultrasound parameters. The studies intended to exclude subjects with polycystic ovary syndrome (PCOS) and subjects with low or no ovarian reserve. One cycle of study medication was administered to each randomized subject. For both studies, the administration of exogenous recombinant FSH [Follistim<sup>®</sup> (follitropin beta for injection)] 150 IU daily was initiated on the morning of Day 2 or 3 of a natural menstrual cycle. Ganirelix acetate injection was administered on the morning of Day 7 or 8 (Day 6 of recombinant FSH administration). The dose of recombinant FSH administered was adjusted according to individual responses starting on the day of initiation of ganirelix acetate. Both recombinant FSH and ganirelix acetate were continued daily until at least three follicles were 17 mm or greater in diameter at which time hCG [Pregnyl<sup>®</sup> (chorionic gonadotropin for injection, USP)] was administered. Following hCG administration, ganirelix acetate and recombinant FSH administration were discontinued. Oocyte retrieval, followed by <content styleCode="italics">in vitro</content> fertilization (IVF) or intracytoplasmic sperm injection (ICSI), was subsequently performed.</paragraph>
                        <paragraph>In a multicenter, double-blind, randomized, dose-finding study, the safety and efficacy of ganirelix acetate were evaluated for the prevention of LH surges in women undergoing COH with recombinant FSH. Ganirelix acetate injection doses ranging from 62.5 mcg to 2,000 mcg and recombinant FSH were administered to 332 patients undergoing COH for IVF (see <linkHtml href="#t301">TABLE II</linkHtml>). Median serum LH on the day of hCG administration decreased with increasing doses of ganirelix acetate. Median serum E<sub>2</sub> (17β-estradiol) on the day of hCG administration was 1475, 1110, and 1160 pg/mL for the 62.5, 125, and 250 mcg doses, respectively. Lower peak serum E<sub>2</sub> levels of 823, 703, and 441 pg/mL were seen at higher doses of ganirelix acetate 500, 1,000, and 2,000 mcg, respectively. The highest pregnancy and implantation rates were achieved with the 250 mcg dose of ganirelix acetate as summarized in <linkHtml href="#t301">Table II</linkHtml>.</paragraph>
                        <table ID="t301" width="100%">
                           <caption>TABLE II: Results from the multicenter, double-blind, randomized, dose-finding study to assess the efficacy of ganirelix acetate to prevent premature LH surges in women undergoing COH with recombinant FSH. </caption>
                           <colgroup>
                              <col width="23.171%" align="left"/>
                              <col width="12.800%" align="left"/>
                              <col width="12.800%" align="left"/>
                              <col width="12.800%" align="left"/>
                              <col width="12.800%" align="left"/>
                              <col width="12.800%" align="left"/>
                              <col width="12.829%" align="left"/>
                           </colgroup>
                           <tfoot>
                              <tr>
                                 <td colspan="7" align="left" valign="top">
                                    <paragraph styleCode="First Footnote">
                                       <content styleCode="italics">(Protocol 38602)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="7" align="left" valign="top">
                                    <paragraph styleCode="First Footnote">* Following initiation of ganirelix acetate therapy. Includes subjects who have complied with daily injections</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="7" align="left" valign="top">
                                    <paragraph styleCode="First Footnote">
                                       <sup>‡</sup> Median values</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="7" align="left" valign="top">
                                    <paragraph styleCode="First Footnote">
                                       <sup>ϒ</sup> Mean (standard deviation)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="7" align="left" valign="top">
                                    <paragraph styleCode="First Footnote">
                                       <sup>†</sup> ET: Embryo Transfer</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="7" align="left" valign="top">
                                    <paragraph styleCode="First Footnote">
                                       <sup>Ω</sup> As evidenced by ultrasound at 5–6 weeks following ET</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="left" valign="top"/>
                                 <td styleCode="Botrule Rrule Toprule" colspan="6" align="center" valign="top">
                                    <content styleCode="bold">Daily Dose (mcg) of Ganirelix Acetate</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top"/>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">
                                    <content styleCode="bold">62.5 mcg</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">
                                    <content styleCode="bold">125 mcg</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">
                                    <content styleCode="bold">250 mcg</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">
                                    <content styleCode="bold">500 mcg</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">
                                    <content styleCode="bold">1,000 mcg</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">
                                    <content styleCode="bold">2,000 mcg</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">No. subjects receiving Ganirelix Acetate</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">31</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">66</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">70</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">69</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">66</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">30</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">No. subjects with ET<sup>†</sup>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">27</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">61</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">62</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">54</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">61</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">27</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">No. of subjects with<br/>LH rise ≥ 10 mIU/mL*</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">4</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">6</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">1</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">0</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">0</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Serum LH (mIU/mL) on day of hCG<sup>‡</sup>
                                    <br/>5<sup>th</sup>–95<sup>th</sup> percentiles</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">3.6<br/>
                                    <br/>0.6–19.9</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">2.5<br/>
                                    <br/>0.6–11.4</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">1.7<br/>
                                    <br/>&lt; 0.25–6.4</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">1.0<br/>
                                    <br/>0.4–4.7</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">0.6<br/>
                                    <br/>&lt; 0.25–2.2</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">0.3<br/>
                                    <br/>&lt; 0.25–0.8</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Serum E<sub>2</sub> (pg/mL) on day of hCG<sup>‡</sup>
                                    <br/>5<sup>th</sup>–95<sup>th</sup> percentiles</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">1475<br/>
                                    <br/>645–3720</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">1110<br/>
                                    <br/>424–3780</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">1160<br/>
                                    <br/>384–3910</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">823<br/>
                                    <br/>279–2720</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">703<br/>
                                    <br/>284–2360</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">441<br/>
                                    <br/>166–1940</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Vital pregnancy rate<sup>Ω</sup>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top"/>
                                 <td styleCode="Botrule Rrule" align="center" valign="top"/>
                                 <td styleCode="Botrule Rrule" align="center" valign="top"/>
                                 <td styleCode="Botrule Rrule" align="center" valign="top"/>
                                 <td styleCode="Botrule Rrule" align="center" valign="top"/>
                                 <td styleCode="Botrule Rrule" align="center" valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">     per attempt, n (%)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">7 (22.6)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">17 (25.8)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">25 (35.7)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">8 (11.6)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">9 (13.6)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">2 (6.7)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">     per transfer, n (%)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">7 (25.9)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">17 (27.9)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">25 (40.3)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">8 (14.8)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">9 (14.8)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">2 (7.4)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Implantation rate (%)<sup>ϒ</sup>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">14.2 (26.8)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">16.3 (30.5)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">21.9 (30.6)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">9.0 (23.7)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">8.5 (21.7)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">4.9 (20.1)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Transient LH rises alone were not deleterious to achieving pregnancy with ganirelix acetate at doses of 125 mcg (3/6 subjects) and 250 mcg (1/1 subjects). In addition, none of the subjects with LH rises ≥ 10 mIU/mL had premature luteinization indicated by a serum progesterone above 2 ng/mL.</paragraph>
                        <paragraph>A multicenter, open-label, randomized study was conducted to assess the efficacy and safety of ganirelix acetate in women undergoing COH. Follicular phase treatment with ganirelix acetate 250 mcg was studied using a luteal phase GnRH agonist as a reference treatment. A total of 463 subjects were treated with ganirelix acetate by subcutaneous injection once daily starting on Day 6 of recombinant FSH treatment. Recombinant FSH was maintained at 150 IU for the first 5 days of ovarian stimulation and was then adjusted by the investigator on the sixth day of gonadotropin use according to individual responses. The results for the ganirelix acetate arm are summarized in <linkHtml href="#t302">Table III</linkHtml>.</paragraph>
                        <table ID="t302" width="100%">
                           <caption>TABLE III: Results from the multicenter, open-label, randomized study to assess the efficacy and safety of ganirelix acetate in women undergoing COH. </caption>
                           <colgroup>
                              <col width="51.000%" align="left"/>
                              <col width="49.000%" align="left"/>
                           </colgroup>
                           <tfoot>
                              <tr>
                                 <td colspan="2" align="left" valign="top">
                                    <paragraph styleCode="First Footnote">
                                       <content styleCode="italics">(Protocol 38607)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="left" valign="top">
                                    <paragraph styleCode="First Footnote">* Following initiation of ganirelix acetate therapy</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="left" valign="top">
                                    <paragraph styleCode="First Footnote">
                                       <sup>‡</sup> Median values</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="left" valign="top">
                                    <paragraph styleCode="First Footnote">
                                       <sup>§</sup> Restricted to subjects with hCG injection</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="left" valign="top">
                                    <paragraph styleCode="First Footnote">
                                       <sup>¥</sup> Mean (standard deviation)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="left" valign="top">
                                    <paragraph styleCode="First Footnote">
                                       <sup>†</sup> ET: Embryo Transfer</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="left" valign="top">
                                    <paragraph styleCode="First Footnote">
                                       <sup>Ω</sup> As evidenced by ultrasound at 12–16 weeks following ET</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="left" valign="top">
                                    <paragraph styleCode="First Footnote">
                                       <sup>λ</sup> Includes one patient who achieved pregnancy with intrauterine induction</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="left" valign="top">
                                    <paragraph styleCode="First Footnote">Some centers were limited to the transfer of ≤ 2 embryos based on local practice standards</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="left" valign="top"/>
                                 <td styleCode="Botrule Rrule Toprule" align="center" valign="top">
                                    <content styleCode="bold">Ganirelix Acetate 250 mcg</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">No. subjects treated</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">463</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Duration of GnRH analog (days)<sup>§, ¥</sup>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">5.4 (2.0)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Duration of recombinant FSH (days)<sup>§, ¥</sup>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">9.6 (2.0)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Serum E<sub>2</sub> (pg/mL) on day of hCG<sup>‡</sup>
                                    <br/>5<sup>th</sup>–95<sup>th</sup> percentiles</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">1190<br/>373–3105</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Serum LH (mIU/mL) on day of hCG<sup>‡</sup>
                                    <br/>5<sup>th</sup>–95<sup>th</sup> percentiles</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">1.6<br/>0.6–6.9</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">No. of subjects with LH rise ≥ 10 mIU/mL<sup>*</sup>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">13</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">No. of follicles &gt; 11 mm<sup>§, ¥</sup>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">10.7 (5.3)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">No. of subjects with oocyte retrieval</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">440</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">No. of oocytes<sup>¥</sup>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">8.7 (5.6)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Fertilization rate</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">62.1%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">No. subjects with ET<sup>†</sup>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">399</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">No. of embryos transferred<sup>¥</sup>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">2.2 (0.6)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">No. of embryos<sup>¥</sup>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">6.0 (4.5)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Ongoing pregnancy rate<sup>Ω, §</sup>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">     per attempt, n (%)<sup>λ</sup>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">94 (20.3)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">     per transfer, n (%)</td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">93 (23.3)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Implantation rate (%)<sup>¥</sup>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="center" valign="top">15.7 (29)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The mean number of days of ganirelix acetate treatment was 5.4 (2–14).</paragraph>
                     </text>
                     <effectiveTime value="20250220"/>
                     <component>
                        <section ID="s12">
                           <id root="a66c8b3f-6a89-4515-825f-80dc60d4d8e7"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">LH Surges</content>
                           </title>
                           <text>
                              <paragraph>The midcycle LH surge initiates several physiologic actions including: ovulation, resumption of meiosis in the oocyte, and luteinization. In 463 subjects administered ganirelix acetate injection 250 mcg, a premature LH surge prior to hCG administration, (LH rise ≥ 10 mIU/mL with a significant rise in serum progesterone &gt; 2 ng/mL, or a significant decline in serum estradiol) occurred in less than 1% of subjects.</paragraph>
                           </text>
                           <effectiveTime value="20250220"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s13">
               <id root="cb5b6b6f-2e67-49d8-84bd-05d10f57adb2"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE
</title>
               <text>
                  <paragraph>Ganirelix Acetate Injection is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation.</paragraph>
               </text>
               <effectiveTime value="20250122"/>
            </section>
         </component>
         <component>
            <section ID="s14">
               <id root="ceb67fe2-f53d-4176-b3d4-fc2777dfbb82"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS
</title>
               <text>
                  <paragraph>Ganirelix acetate is contraindicated under the following conditions:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Known hypersensitivity to ganirelix acetate or to any of its components including dry natural rubber/latex (see <content styleCode="bold">
                           <linkHtml href="#s29">HOW SUPPLIED</linkHtml>
                        </content>).</item>
                     <item>Known hypersensitivity to GnRH or any other GnRH analog.</item>
                     <item>Known or suspected pregnancy (see <content styleCode="bold">
                           <linkHtml href="#s16">PRECAUTIONS</linkHtml>
                        </content>).</item>
                  </list>
               </text>
               <effectiveTime value="20250220"/>
            </section>
         </component>
         <component>
            <section ID="s15">
               <id root="8f6c1064-9fa3-495b-a65b-256aaed6d0b2"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS
</title>
               <text>
                  <paragraph>Ganirelix acetate injection should be prescribed by physicians who are experienced in infertility treatment. Before starting treatment with ganirelix acetate, pregnancy must be excluded. Safe use of ganirelix acetate during pregnancy has not been established (see <content styleCode="bold">
                        <linkHtml href="#s14">CONTRAINDICATIONS</linkHtml>
                     </content> and <content styleCode="bold">
                        <linkHtml href="#s16">PRECAUTIONS</linkHtml>
                     </content>).</paragraph>
               </text>
               <effectiveTime value="20230921"/>
            </section>
         </component>
         <component>
            <section ID="s16">
               <id root="692aa0e8-0319-4cb6-b33a-c99fdf961fcd"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS
</title>
               <effectiveTime value="20250220"/>
               <component>
                  <section ID="s17">
                     <id root="c2a94a97-215c-4e4b-bccd-b3464f384447"/>
                     <code code="34072-9" codeSystem="2.16.840.1.113883.6.1" displayName="GENERAL PRECAUTIONS SECTION"/>
                     <title>General
</title>
                     <text>
                        <paragraph>Special care should be taken in women with signs and symptoms of active allergic conditions. Cases of hypersensitivity reactions (both generalized and local), including anaphylaxis (including anaphylactic shock), angioedema and urticaria, have been reported with ganirelix acetate, as early as with the first dose, during post-marketing surveillance (see <content styleCode="bold">
                              <linkHtml href="#s25">ADVERSE REACTIONS</linkHtml>
                           </content>). If a hypersensitivity reaction is suspected, ganirelix acetate should be discontinued and appropriate treatment administered. In the absence of clinical experience, ganirelix acetate treatment is not advised in women with severe allergic conditions.</paragraph>
                        <paragraph>The rigid needle shield of this product is not made with natural rubber/latex (see <content styleCode="bold">
                              <linkHtml href="#s14"> CONTRAINDICATIONS </linkHtml>
                           </content> and <content styleCode="bold">
                              <linkHtml href="#s29"> HOW SUPPLIED</linkHtml>
                           </content>).</paragraph>
                     </text>
                     <effectiveTime value="20250220"/>
                  </section>
               </component>
               <component>
                  <section ID="s18">
                     <id root="62d5307a-3ebf-4ab8-a35a-6593e9736906"/>
                     <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
                     <title>Information for Patients
</title>
                     <text>
                        <paragraph>Prior to therapy with ganirelix acetate, patients should be informed of the duration of treatment and monitoring procedures that will be required. The risk of possible adverse reactions should be discussed (see <content styleCode="bold">
                              <linkHtml href="#s25">ADVERSE REACTIONS</linkHtml>
                           </content>).</paragraph>
                        <paragraph>Ganirelix acetate should not be prescribed if the patient is pregnant.</paragraph>
                     </text>
                     <effectiveTime value="20231012"/>
                  </section>
               </component>
               <component>
                  <section ID="s19">
                     <id root="d4b22e1d-423a-4e0f-b5b3-b56a63b4f771"/>
                     <code code="34075-2" codeSystem="2.16.840.1.113883.6.1" displayName="LABORATORY TESTS SECTION"/>
                     <title>Laboratory Tests
</title>
                     <text>
                        <paragraph>A neutrophil count ≥ 8.3 (x 10<sup>9</sup>/L) was noted in 11.9% (up to 16.8 x 10<sup>9</sup>/L) of all subjects treated within the adequate and well-controlled clinical trials. In addition, downward shifts within the ganirelix acetate group were observed for hematocrit and total bilirubin. The clinical significance of these findings was not determined.</paragraph>
                     </text>
                     <effectiveTime value="20250220"/>
                  </section>
               </component>
               <component>
                  <section ID="s20">
                     <id root="2a40ffe7-0eed-4b74-80e3-0e9cd533384b"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>Drug Interactions
</title>
                     <text>
                        <paragraph>No formal drug-drug interaction studies have been performed.</paragraph>
                     </text>
                     <effectiveTime value="20230921"/>
                  </section>
               </component>
               <component>
                  <section ID="s21">
                     <id root="1c0f79a0-9326-4c86-b866-028034233c7a"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>Carcinogenesis and Mutagenesis, Impairment of Fertility
</title>
                     <text>
                        <paragraph>Long-term toxicity studies in animals have not been performed with ganirelix acetate to evaluate the carcinogenic potential of the drug. Ganirelix acetate did not induce a mutagenic response in the Ames test <content styleCode="italics">(S. typhimurium</content> and <content styleCode="italics">E. coli</content>) or produce chromosomal aberrations in <content styleCode="italics">in vitro</content> assay using Chinese Hamster Ovary cells.</paragraph>
                     </text>
                     <effectiveTime value="20230921"/>
                  </section>
               </component>
               <component>
                  <section ID="s22">
                     <id root="5ec0a608-7699-45f3-8885-aa2a0c68201f"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>Pregnancy
</title>
                     <text>
                        <paragraph>Ganirelix acetate is contraindicated in pregnant women. When administered from Day 7 to near term to pregnant rats and rabbits at doses up to 10 and 30 mcg/day (approximately 0.4 to 3.2 times the human dose based on body surface area), ganirelix acetate increased the incidence of litter resorption. There was no increase in fetal abnormalities. No treatment-related changes in fertility, physical, or behavioral characteristics were observed in the offspring of female rats treated with ganirelix acetate during pregnancy and lactation.</paragraph>
                        <paragraph>The effects on fetal resorption are logical consequences of the alteration in hormonal levels brought about by the antigonadotropic properties of this drug and could result in fetal loss in humans. Therefore, this drug should not be used in pregnant women (see <content styleCode="bold">
                              <linkHtml href="#s14">CONTRAINDICATIONS</linkHtml>
                           </content>).</paragraph>
                     </text>
                     <effectiveTime value="20230921"/>
                  </section>
               </component>
               <component>
                  <section ID="s23">
                     <id root="d906f650-a96e-4f54-9f00-1c7854ab3039"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>Nursing Mothers
</title>
                     <text>
                        <paragraph>Ganirelix acetate should not be used by lactating women. It is not known whether this drug is excreted in human milk.</paragraph>
                     </text>
                     <effectiveTime value="20230921"/>
                  </section>
               </component>
               <component>
                  <section ID="s24">
                     <id root="af0e09aa-d459-4c78-b704-5774fffdc485"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>Geriatric Use
</title>
                     <text>
                        <paragraph>Clinical studies with ganirelix acetate did not include a sufficient number of subjects aged 65 and over.</paragraph>
                     </text>
                     <effectiveTime value="20230921"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s25">
               <id root="04acf69d-5515-4fb4-871c-6f48b63e461e"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS
</title>
               <text>
                  <paragraph>The safety of ganirelix acetate was evaluated in two randomized, parallel-group, multicenter controlled clinical studies. Treatment duration for ganirelix acetate ranged from 1 to 14 days. <linkHtml href="#t303">Table IV</linkHtml> represents adverse events (AEs) from first day of ganirelix acetate administration until confirmation of pregnancy by ultrasound at an incidence of ≥ 1% in ganirelix acetate-treated subjects without regard to causality.</paragraph>
                  <table ID="t303" width="100%">
                     <caption>TABLE IV: Incidence of common adverse events (Incidence ≥ 1% in ganirelix acetate-treated subjects). Completed controlled clinical studies (All-subjects-treated group). </caption>
                     <colgroup>
                        <col width="51.500%" align="left"/>
                        <col width="48.500%" align="left"/>
                     </colgroup>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="left" valign="top">
                              <content styleCode="bold">Adverse Events Occurring in </content>≥<content styleCode="bold"> 1%</content>
                           </td>
                           <td styleCode="Botrule Rrule Toprule" align="center" valign="top">
                              <content styleCode="bold">Ganirelix Acetate N=794</content>
                              <br/>
                              <content styleCode="bold">% (n)</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Abdominal Pain (gynecological)</td>
                           <td styleCode="Botrule Rrule" align="center" valign="top">4.8 (38)</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Death Fetal</td>
                           <td styleCode="Botrule Rrule" align="center" valign="top">3.7 (29)</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Headache</td>
                           <td styleCode="Botrule Rrule" align="center" valign="top">3.0 (24)</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Ovarian Hyperstimulation Syndrome</td>
                           <td styleCode="Botrule Rrule" align="center" valign="top">2.4 (19)</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Vaginal Bleeding</td>
                           <td styleCode="Botrule Rrule" align="center" valign="top">1.8 (14)</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Injection Site Reaction</td>
                           <td styleCode="Botrule Rrule" align="center" valign="top">1.1 (9)</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Nausea</td>
                           <td styleCode="Botrule Rrule" align="center" valign="top">1.1 (9)</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" align="left" valign="top">Abdominal Pain (gastrointestinal)</td>
                           <td styleCode="Botrule Rrule" align="center" valign="top">1.0 (8)</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>During post-marketing surveillance, rare cases of hypersensitivity reactions, including anaphylaxis (including anaphylactic shock), angioedema and urticaria have been reported with ganirelix acetate, as early as with the first dose (see <content styleCode="bold">
                        <linkHtml href="#s16">PRECAUTIONS</linkHtml>
                     </content>).</paragraph>
               </text>
               <effectiveTime value="20231012"/>
               <component>
                  <section ID="s26">
                     <id root="1c4664bb-666a-43bf-bb8f-d281069f800a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Congenital Anomalies</content>
                        </paragraph>
                        <paragraph>An observational study in more than 1,000 newborns compared the incidence of congenital anomalies in newborns of women administered ganirelix acetate to historical controls of a GnRH agonist. This study demonstrated that the incidence of congenital anomalies in children born after COH treatment in women using ganirelix acetate was comparable with that reported after a COH treatment cycle using a GnRH agonist.</paragraph>
                        <paragraph>
                           <br/>The incidence of congenital malformations after some Assisted Reproductive Technologies (ART) [specifically <content styleCode="italics">in vitro</content> fertilization (IVF) or intracytoplasmic sperm injection (ICSI)] may be slightly higher than after spontaneous conception. This slightly higher incidence is thought to be related to differences in parental characteristics (e.g., maternal age, maternal and paternal genetic background, sperm characteristics) and to the higher incidence of multi-fetal gestations after IVF or ICSI. The causal relationship between these congenital anomalies and ganirelix acetate injection is unknown.</paragraph>
                     </text>
                     <effectiveTime value="20231012"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s27">
               <id root="ccec709f-3c2a-4d5d-99f7-51d0ff672c9c"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE
</title>
               <text>
                  <paragraph>There have been no reports of overdosage with ganirelix acetate in humans.</paragraph>
               </text>
               <effectiveTime value="20230921"/>
            </section>
         </component>
         <component>
            <section ID="s28">
               <id root="9207b43b-78fe-47e6-82b6-af5ba21d4d76"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION
</title>
               <text>
                  <paragraph>After initiating FSH therapy on Day 2 or 3 of the cycle, ganirelix acetate injection 250 mcg may be administered subcutaneously once daily during the mid to late portion of the follicular phase. By taking advantage of endogenous pituitary FSH secretion, the requirement for exogenously administered FSH may be reduced. Treatment with ganirelix acetate should be continued daily until the day of hCG administration. When a sufficient number of follicles of adequate size are present, as assessed by ultrasound, final maturation of follicles is induced by administering hCG. The administration of hCG should be withheld in cases where the ovaries are abnormally enlarged on the last day of FSH therapy to reduce the chance of developing OHSS (Ovarian Hyperstimulation Syndrome).</paragraph>
                  <paragraph>
                     <content styleCode="bold">Directions for Using Ganirelix Acetate Injection</content>
                  </paragraph>
                  <list listType="ordered" styleCode="Arabic">
                     <item>Ganirelix acetate injection is supplied in a single dose, sterile, prefilled syringe and is intended for SUBCUTANEOUS administration only.</item>
                     <item>Air bubble(s) may be seen in the pre-filled syringe. This is expected, and removal of the air bubble(s) is not needed.</item>
                     <item>Wash hands thoroughly with soap and water.</item>
                     <item>The most convenient sites for SUBCUTANEOUS injection are in the abdomen around the navel or upper thigh.</item>
                     <item>The injection site should be swabbed with a disinfectant to remove any surface bacteria. Clean about two inches around the point where the needle will be inserted and let the disinfectant dry for at least one minute before proceeding.</item>
                     <item>With syringe held upward, remove needle cover.</item>
                     <item>Pinch up a large area of skin between the finger and thumb. Vary the injection site a little with each injection.</item>
                     <item>The needle should be inserted at the base of the pinched-up skin at an angle of 45–90° to the skin surface.</item>
                     <item>When the needle is correctly positioned, it will be difficult to draw back on the plunger. If any blood is drawn into the syringe, the needle tip has penetrated a vein or artery. If this happens, withdraw the needle slightly and reposition the needle without removing it from the skin. Alternatively, remove the needle and use a new, sterile, prefilled syringe. Cover the injection site with a swab containing disinfectant and apply pressure; the site should stop bleeding within one or two minutes.</item>
                     <item>Once the needle is correctly placed, depress the plunger slowly and steadily, so the solution is correctly injected and the skin is not damaged.</item>
                     <item>Pull the syringe out quickly and apply pressure to the site with a swab containing disinfectant.</item>
                     <item>Use the sterile, prefilled syringe only once. Discard the unused portion and dispose of it properly.</item>
                  </list>
               </text>
               <effectiveTime value="20230921"/>
            </section>
         </component>
         <component>
            <section ID="s29">
               <id root="188f3a3d-ffc3-4435-994a-69b45bdc96df"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED
</title>
               <text>
                  <paragraph>Ganirelix Acetate Injection is a colorless, aqueous solution of ganirelix acetate and is supplied as follows:</paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <colgroup>
                        <col width="17.361%" align="left"/>
                        <col width="54.848%" align="left"/>
                        <col width="27.791%" align="left"/>
                     </colgroup>
                     <tbody>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">NDC</content>
                           </td>
                           <td align="left" valign="top">
                              <content styleCode="bold">Ganirelix Acetate Injection (250 mcg per 0.5 mL)</content>
                           </td>
                           <td align="left" valign="top">
                              <content styleCode="bold">Package Factor</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">71288-<content styleCode="bold">554</content>-80</td>
                           <td align="left" valign="top">Disposable, ready for use, prefilled Single-Dose Syringe containing 250 mcg per 0.5 mL of ganirelix acetate, closed with a rubber piston that does not contain latex. Each prefilled syringe is affixed with a 29 gauge x ½-inch needle <content styleCode="bold">closed by a rigid needle shield that is not made with natural rubber latex</content> (see <content styleCode="bold">
                                 <linkHtml href="#s14"> CONTRAINDICATIONS </linkHtml>
                              </content> and <content styleCode="bold">
                                 <linkHtml href="#s16"> PRECAUTIONS</linkHtml>
                              </content>, <content styleCode="bold">
                                 <linkHtml href="#s17"> General</linkHtml>
                              </content>).</td>
                           <td align="left" valign="top">1 syringe per carton</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph/>
               </text>
               <effectiveTime value="20250220"/>
               <component>
                  <section ID="s30">
                     <id root="465e9119-9f1c-426b-aef1-767ad8867d18"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <title>Storage
</title>
                     <text>
                        <paragraph>Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature.]</paragraph>
                        <paragraph>
                           <content styleCode="bold">Protect from light.</content>
                        </paragraph>
                        <paragraph>Discard unused portion.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Sterile, Nonpyrogenic, Preservative-free.<br/>The container closure is not made with natural rubber latex.</content>
                        </paragraph>
                        <paragraph>Brands listed are the trademarks of their respective owners.</paragraph>
                        <paragraph>meitheal<sub>®</sub>
                           <br/>Mfd. for Meitheal Pharmaceuticals<br/>Chicago, IL 60631 (USA)<br/>©2025 Meitheal Pharmaceuticals Inc.</paragraph>
                        <paragraph>Mfd. by Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.<br/>Nanjing, China 210061</paragraph>
                        <paragraph>Revised: February 2025</paragraph>
                        <paragraph>8H6AAM9-03</paragraph>
                     </text>
                     <effectiveTime value="20250220"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s31">
               <id root="5a09998e-741f-41a6-bd9c-87edfa9a4908"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL – Ganirelix Acetate Injection, 250 mcg per 0.5 mL Syringe Label</title>
               <text>
                  <paragraph>NDC 71288-<content styleCode="bold">554</content>-80</paragraph>
                  <paragraph>Rx Only</paragraph>
                  <paragraph>
                     <content styleCode="bold">Ganirelix Acetate Injection</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">250 mcg per 0.5 mL</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For Subcutaneous Use Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">250 mcg Single-Dose Sterile Prefilled Syringe - 29 gauge by 1/2” needle</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Protect from light.</content> Discard unused portion.</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L7e39ea65-a84d-484c-b7e9-9ab96835dc7d"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250220"/>
               <component>
                  <observationMedia ID="L7e39ea65-a84d-484c-b7e9-9ab96835dc7d">
                     <text>PRINCIPAL DISPLAY PANEL – Ganirelix Acetate Injection, 250 mcg per 0.5 mL Syringe Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="gan05-0000-02-v4.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s32">
               <id root="a235cb7a-c7e4-47b2-9798-cc6ecfaeeae4"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL – Ganirelix Acetate Injection, 250 mcg per 0.5 mL Carton</title>
               <text>
                  <paragraph>NDC 71288-<content styleCode="bold">554</content>-80</paragraph>
                  <paragraph>
                     <content styleCode="bold">1 x 250 mcg Single-Dose Sterile Prefilled Syringe</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">29 gauge by 1/2” needle</content>
                  </paragraph>
                  <paragraph>Rx Only</paragraph>
                  <paragraph>
                     <content styleCode="bold">Ganirelix Acetate Injection</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">250 mcg per 0.5 mL</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For Subcutaneous Use Only</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="Ld482d4a2-79e0-456b-a442-32c02d236df8"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250220"/>
               <component>
                  <observationMedia ID="Ld482d4a2-79e0-456b-a442-32c02d236df8">
                     <text>PRINCIPAL DISPLAY PANEL – Ganirelix Acetate Injection, 250 mcg per 0.5 mL Carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="gan05-0000-03-v7.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>